Banco Santander-Chile (NYSE:SAN) delivered a profit and beat Wall Street’s expectations, BUT came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 0.68%.
Banco Santander-Chile Earnings Cheat Sheet
Revenue: Decreased 79.12% to $10.32 billion from the year-earlier quarter.
Actual vs. Wall St. Expectations: Banco Santander-Chile reported adjusted EPS income of $0.1 per share. By that measure, the company beat the mean analyst estimate of $0. It missed the average revenue estimate of $73.4 billion.
Quoting Management: “Lyxumia, as the first GLP-1 receptor agonist approved in Japan for use in combination with basal insulin, will be a valuable new treatment option for many of the country’s 6 million plus people living with type 2 diabetes,” said Pierre Chancel, Senior Vice-President, Global Diabetes at Sanofi. “The MHLW decision immediately enables the use of Lyxumia, which works in a way that complements basal insulin.”
Key Stats (on next page)…
Revenue increased 121.36% from $4.66 billion in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a loss of $0 and has not changed. For the current year, the average estimate has moved down from a profit of $0.75 to a profit of $0.69 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)